<DOC>
	<DOCNO>NCT02596035</DOCNO>
	<brief_summary>This protocol generate safety data nivolumab monotherapy advanced Renal Cell Carcinoma ( RCC ) patient primary objective , assessment high grade immune-mediated adverse event ( IMAE ) patient population treat nivolumab . In addition continue investigation safety RCC patient clear cell histology prior treatment anti- vascular endothelial growth factor ( VEGF ) therapy , study explore safety efficacy data RCC patient non-clear cell histology RCC patient either histology brain metastasis .</brief_summary>
	<brief_title>A Safety Trial Nivolumab Patients With Advanced Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Advanced Metastatic renal cell carcinoma ( RCC ) Predominant clear cell histology : 1 . At least 1 2 prior systemic anti vascular endothelial growth factor ( antiVEGF ) treatments 2 . No 3 total prior systemic treatment regimen advance metastatic set 3 . Subjects prior treatment mechanistic target rapamycin ( mTOR ) eligible Nonclear cell histology : 03 prior systemic therapy may include mTOR inhibitor Brain metastasis allow asymptomatic , without edema , receive corticosteroid radiation Performance Status ( PS ) : â‰¥ 70 % Karnofsky Performance Scale ( KPS ) All Memorial SloanKettering Cancer Center ( MSKCC ) prognostic score allow Subjects active autoimmune disease history know autoimmune disease History severe hypersensitivity reaction monoclonal antibody Prior malignancy , active within last 3 year , except locally curable cancer apparently cure Known HIV AIDSrelated illness Any positive test Hepatitis B Hepatitis C virus indicate acute chronic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>